{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/68beeb540e15f0d455abc0b7/6997489ff8a4f13cfffa7eae?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AL Amyloidosis: Diagnosis and Management","description":"<p>An audio summary of the diagnosis and management of AL amyloidosis based on:</p><p><br></p><ul><li><a href=\"https://www.tandfonline.com/doi/10.1080/13506129.2021.2002841?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" rel=\"noopener noreferrer\" target=\"_blank\">Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis EHA-ISA working group guidelines</a></li><li><a href=\"https://www.tandfonline.com/doi/10.1080/13506129.2022.2093635?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" rel=\"noopener noreferrer\" target=\"_blank\">Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis EHA-ISA working group guidelines</a></li><li><a href=\"https://www.nice.org.uk/guidance/ta959\" rel=\"noopener noreferrer\" target=\"_blank\">NICE technology appraisal: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis</a></li></ul>","author_name":"Richard Buka"}